While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Common Antidepressant Reduces Meth Use and High-Risk Sexual Behavior for Gay and Bisexual Men and Transgender Women
Could this give hope to people struggling with crystal meth addiction?
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.